On 3 October 2011 European Centre for Disease Prevention and Control (ECDC) and representatives of the European Vaccine Manufacturers  met at ECDC in Stockholm for a regular scheduled meeting about the use of vaccines for prevention of seasonal and pandemic influenza. ECDC Director Marc Sprenger opened the meeting and ECDC influenza experts held different presentations, such as burden of influenza disease in the EU, risk groups for severe influenza disease, personal protective measures, pandemic influenza preparedness, seasonal influenza vaccines, communication.
The Declarations of Interest for ECDC Influenza Staff and the ECDC Director are available here under ECDC Transparency.

​This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.